Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma

Seong-Lan Yu1 Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, Republic of Korea, [email protected]

Dong Chul Lee2 Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea

Seung Woo Baek3 Department of Oncology-Hematology, Konyang University Hospital, Daejeon, Republic of Korea, [email protected]

Do Yeun Cho3 Department of Oncology-Hematology, Konyang University Hospital, Daejeon, Republic of Korea, [email protected]

Jong Gwon Choi3 Department of Oncology-Hematology, Konyang University Hospital, Daejeon, Republic of Korea, [email protected]Correspondence[email protected]

JaeKu Kang1 Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, Republic of Korea, [email protected]Correspondence[email protected]

Pages 6379-6389 | Published online: 27 Nov 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

AlamMRatnerDCutaneous squamous-cell carcinomaN Engl J Med20013441397598311274625
PubMed Web of Science ®Google Scholar
EuvrardSKanitakisJClaudyASkin cancers after organ transplantationN Engl J Med2003348171681169112711744
PubMed Web of Science ®Google Scholar
LindelöfBSigurgeirssonBGäbelHSternRSIncidence of skin cancer in 5356 patients following organ transplantationBr J Dermatol2000143351351910971322
PubMed Web of Science ®Google Scholar
IkegawaSSaidaTObayashiHCisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skinJ Dermatol19891632272302551943
PubMedGoogle Scholar
KhansurTKennedyACisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skinCancer1991678203020322004320
PubMed Web of Science ®Google Scholar
GuthrieTHPorubskyESLuxenbergMNShahKJWurtzKLWatsonPRCisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapyJ Clin Oncol1990823423462405109
PubMed Web of Science ®Google Scholar
SadekHAzliNWendlingJLTreatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycinCancer1990668169216961698529
PubMed Web of Science ®Google Scholar
ShinDMGlissonBSKhuriFRPhase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancerJ Clin Oncol200220236437011786562
PubMed Web of Science ®Google Scholar
ReigneauMRobertCRoutierEEfficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomasBr J Dermatol2015173252753425704233
PubMed Web of Science ®Google Scholar
LuSMLienWWConcurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckAm J Clin Oncol2018411959926353121
PubMed Web of Science ®Google Scholar
FerrisRLBlumenscheinGFayetteJNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckN Engl J Med2016375191856186727718784
PubMed Web of Science ®Google Scholar
ChowLQMHaddadRGuptaSAntitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortJ Clin Oncol201634323838384527646946
PubMed Web of Science ®Google Scholar
CampbellSBWalkerRTaiSSJiangQRussGRRandomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancerAm J Transplant20121251146115622420843
PubMed Web of Science ®Google Scholar
EuvrardSMorelonERostaingLTUMORAPA Study GroupSirolimus and secondary skin-cancer prevention in kidney transplantationN Engl J Med2012367432933922830463
PubMed Web of Science ®Google Scholar
Hoogendijk-van den AkkerJMHardenPNHoitsmaAJTwo-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimusJ Clin Oncol201331101317132323358973
PubMed Web of Science ®Google Scholar
NewmanRMMobascherAMangoldUAntizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repressionJ Biol Chem200427940415044151115277517
PubMed Web of Science ®Google Scholar
LiuYLiQZhouLCancer drug resistance: redox resetting renders a wayOncotarget2016727427404276127057637
PubMedGoogle Scholar
LauATWangYChiuJFReactive oxygen species: current knowledge and applications in cancer research and therapeuticJ Cell Biochem2008104265766718172854
PubMed Web of Science ®Google Scholar
PyoCWChoiJHOhSMChoiSYOxidative stress-induced cyclin D1 depletion and its role in cell cycle processingBiochim Biophys Acta20131830115316532523920145
PubMed Web of Science ®Google Scholar
ShenYXuJJinJTangHLiangJCyclin D1 expression in Bowen’s disease and cutaneous squamous cell carcinomaMol Clin Oncol20142454554824940492
PubMedGoogle Scholar
NoelEEYeste-VelascoMMaoXThe association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancersAm J Pathol201017662607261520395447
PubMed Web of Science ®Google Scholar
KennedyBKLammingDWThe Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and AgingCell Metab2016236990100327304501
PubMed Web of Science ®Google Scholar
ShimobayashiMHallMNMaking new contacts: the mTOR network in metabolism and signalling crosstalkNat Rev Mol Cell Biol201415315516224556838
PubMed Web of Science ®Google Scholar
JewellJLRussellRCGuanKLAmino acid signalling upstream of mTORNat Rev Mol Cell Biol201314313313923361334
PubMed Web of Science ®Google Scholar
ZoncuREfeyanASabatiniDMmTOR: from growth signal integration to cancer, diabetes and ageingNat Rev Mol Cell Biol2011121213521157483
PubMed Web of Science ®Google Scholar
SchulerWSedraniRCottensSSDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivoTransplantation199764136429233698
PubMed Web of Science ®Google Scholar
YuPLairdADduXCharacterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayMol Cancer Ther20141351078109124634413
PubMed Web of Science ®Google Scholar
XieJWangXProudCGmTOR inhibitors in cancer therapyF1000Res201652078
Google Scholar
HoldaasHDe SimonePZuckermannAEverolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateJ Transplant20162016111
Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date